Article

Hydroxysteroid 17-beta dehydrogenase 13 <i>(Hsd17b13)</i> knockdown attenuates liver steatosis in high-fat diet obese mice

2024-03-01

Abstract excerpt

<h4>ABSTRACT</h4> Hydroxysteroid 17-beta dehydrogenase 13 ( HSD17B13 ) loss-of-function gene variants are associated with decreased risk of ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD). Our RNA-seq analysis of steatotic liver from obese mice -/+ Fenretinide treatment identified major beneficial effects of Fenretinide on hepatic gene expression including Hsd17b13 . We sought to determine th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2b35512b-e19f-5e91-b110-e464f1892ee7
DOI: 10.1101/2024.02.27.582262

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Hydroxysteroid 17-beta dehydrogenase 13 <i>(Hsd17b13)</i> knockdown attenuates liver steatosis in high-fat diet obese miceDOI 10.1101/2024.02.27.582262Read

HSD17B13: A Potential Therapeutic Target for NAFLDSemantic proximity Read

17‐Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver DiseaseSemantic proximity Read

HSD17B13 Couples Hepatocyte Lipid Metabolism to Stellate Cell Activation via TGFb-1 SignalingSemantic proximity Read

Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort.Semantic proximity Read

A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.Semantic proximity Read

Cholesterol-associated Locus <i>EHBP1</i> Protects against NASH FibrosisSemantic proximity Read

Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic TargetSemantic proximity Read

Sex Dimorphism of Nonalcoholic Fatty Liver Disease (NAFLD) in Pparg-Null Mice.Semantic proximity Read

Hepatocyte high-mobility group box 1 protects against steatosis and cellular stress during high fat diet feedingSemantic proximity Read

Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitisSemantic proximity Read

Fenretinide inhibits obesity and fatty liver disease but induces Smpd3 to increase serum ceramides and worsen atherosclerosis in LDLR-/- miceSemantic proximity Read

Hepatocyte Circadian Clocks Control Cholesterol Metabolism and Protect From Metabolic Dysfunction-Associated Steatohepatitis (MASH)Semantic proximity Read